Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 4/20 | 0.40 |
| ▸ | PDK1 | Q15118 | 5/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | PPIB | P23284 | 1/20 | 0.32 |
| ▸ | IRAK4 | Q9NWZ3 | 3/20 | 0.31 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
| ▸ | PIK3R2 | O00459 | 1/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.31 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.31 |
| ▸ | PIK3R5 | Q8WYR1 | 1/20 | 0.31 |
| ▸ | PIK3R3 | Q92569 | 1/20 | 0.31 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25874576 | 0.83 | EPHA2 (0.44) | CYP19A1 | |
| SCHEMBL25292333 | 0.75 | CYP19A1 (0.35) | CYP19A1 | |
| SCHEMBL25238333 | 0.75 | CYP19A1 (0.35) | CYP19A1 | |
| SCHEMBL26117273 | 0.73 | CNR1 (0.36) | CYP19A1PDK1HPGDPPIB | |
| SCHEMBL26115781 | 0.73 | CNR1 (0.36) | CYP19A1PDK1HPGDPPIB | |
| SCHEMBL26115783 | 0.73 | CNR1 (0.36) | CYP19A1PDK1HPGDPPIB | |
| SCHEMBL16876018 | 0.72 | PKM (0.38) | CYP19A1PDK1HPGDPIK3CDPIK3R2 | |
| SCHEMBL27139836 | 0.71 | KRAS (0.35) | CYP19A1PDK1PPIB | |
| SCHEMBL27139834 | 0.71 | KRAS (0.35) | CYP19A1PDK1PPIB | |
| SCHEMBL3488393 | 0.70 | PDK1 (0.42) | CYP19A1PDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219973-A1 | DEUBIQUITINASE INHIBITORS AND METHODS OF USE THEREOF | MOLECURE S.A. (PL) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219973-A1 | DEUBIQUITINASE INHIBITORS AND METHODS OF USE THEREOF | USP7, USP28, USP1 | CYP19A1 2485/4885PDK1 3685/4885HPGD 3732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.